71 related articles for article (PubMed ID: 20629032)
1. The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors.
Koos B; Jeibmann A; Lünenbürger H; Mertsch S; Nupponen NN; Roselli A; Leuschner I; Paulus W; Frühwald MC; Hasselblatt M
Cancer; 2010 Nov; 116(21):5075-81. PubMed ID: 20629032
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
3. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
4. Gleevec casts a pox on poxviruses.
McFadden G
Nat Med; 2005 Jul; 11(7):711-2. PubMed ID: 16015355
[No Abstract] [Full Text] [Related]
5. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Noren NK; Foos G; Hauser CA; Pasquale EB
Nat Cell Biol; 2006 Aug; 8(8):815-25. PubMed ID: 16862147
[TBL] [Abstract][Full Text] [Related]
6. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
7. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
8. c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3.
Li X; Ma Q; Wang J; Liu X; Yang Y; Zhao H; Wang Y; Jin Y; Zeng J; Li J; Song L; Li X; Li P; Qian X; Cao C
Cell Death Differ; 2010 Aug; 17(8):1277-87. PubMed ID: 20150913
[TBL] [Abstract][Full Text] [Related]
9. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility.
Poppe M; Feller SM; Römer G; Wessler S
Oncogene; 2007 May; 26(24):3462-72. PubMed ID: 17160020
[TBL] [Abstract][Full Text] [Related]
11. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
[TBL] [Abstract][Full Text] [Related]
12. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
13. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
14. c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase.
Kamath R; Jiang Z; Sun G; Yalowich JC; Baskaran R
Mol Pharmacol; 2007 Jan; 71(1):61-72. PubMed ID: 17021249
[TBL] [Abstract][Full Text] [Related]
15. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
16. Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates.
Brueggemeier SB; Wu D; Kron SJ; Palecek SP
Biomacromolecules; 2005; 6(5):2765-75. PubMed ID: 16153117
[TBL] [Abstract][Full Text] [Related]
17. The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.
Nicolini FE; Chabane K; Cayuela JM; Rousselot P; Thomas X; Hayette S
Haematologica; 2006 Jan; 91(1):137-8. PubMed ID: 16434384
[TBL] [Abstract][Full Text] [Related]
18. Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry.
Kalesh KA; Liu K; Yao SQ
Org Biomol Chem; 2009 Dec; 7(24):5129-36. PubMed ID: 20024108
[TBL] [Abstract][Full Text] [Related]
19. c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis.
Vázquez MC; Vargas LM; Inestrosa NC; Alvarez AR
J Cell Physiol; 2009 Jul; 220(1):136-43. PubMed ID: 19306298
[TBL] [Abstract][Full Text] [Related]
20. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
